How to choose a more appropriate dosage of Crizotinib?

Crizotinib is a targeted drug commonly used to treat non-small cell lung cancer (NSCLC). The selection of its dosage is crucial to the treatment effect and patient tolerance. Generally speaking, the dosage selection of crizotinib is mainly based on the patient's specific condition, weight, liver and kidney function, and drug tolerance. Common dosage specifications include 200mg and 250mg capsules or tablets, with each box containing 60 capsules.

Usually, doctors will determine the starting dose based on the patient's constitution and severity of the condition. The initial dose for most patients is 250 mg twice a day, which is the most widely used standard dose in clinical practice. This dose has been proven in multiple clinical trials to be effective in inhibiting tumor growth and is well tolerated by most patients. However, for patients with impaired liver function or those who are older and frail, doctors may recommend starting with a lower dose, such as 200 mg, to reduce the risk of side effects.

During treatment, the patient's response and side effect profile will influence dosage adjustments. If obvious adverse reactions occur, such as abnormal liver function, electrocardiogram changes, or severe gastrointestinal symptoms, the doctor may temporarily reduce the dose or extend the dosing interval, or even temporarily discontinue the drug, and then resume the original dose or adjust to a lower dose after the symptoms are relieved. This can ensure the efficacy while maximizing patient safety.

Finally, patients should strictly follow the doctor's instructions when using crizotinib and do not adjust the dosage on their own. Regular follow-up and monitoring of liver and kidney function, electrocardiogram and tumor response are important basis for reasonable dose selection and adjustment. Reasonable selection and adjustment of the dosage of crizotinib can help patients obtain the best therapeutic effect, reduce drug side effects, and improve quality of life.

Reference materials:https://go.drugbank.com/drugs/DB08865